Complement 1 inhibitor is a regulator of the alternative complement pathway - Wikidata - awgldk - TriplyDB

Complement 1 inhibitor is a regulator of the alternative complement pathway

Complement 1 inhibitor is a regulator of the alternative complement pathway

http://www.wikidata.org/entity/Q36369674

about

Borrelia valaisiana resist complement-mediated killing independently of the recruitment of immune regulators and inactivation of complement components The role of complement system in septic shock C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease BIOLOGICAL ACTIVITIES OF C1 INHIBITOR SERPING1 polymorphisms in polypoidal choroidal vasculopathy.Serping1/C1 Inhibitor Affects Cortical Development in a Cell Autonomous and Non-cell Autonomous Manner.Oversulfated chondroitin sulfate inhibits the complement classical pathway by potentiating C1 inhibitor.Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria Complement in ischemia reperfusion injury.The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q Cross-talk between the complement and the kinin system in vascular permeability.Extracellular gelatinase of Enterococcus faecalis destroys a defense system in insect hemolymph and human serum.Interactions between coagulation and complement--their role in inflammation Regulation of Complement and Contact System Activation via C1 Inhibitor Potentiation and Factor XIIa Activity Modulation by Sulfated Glycans - Structure-Activity Relationships The effect of C1 inhibitor on myocardial ischemia and reperfusion injury.The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema.Natural antibodies, autoantibodies and complement activation in tissue injury.C1 inhibitor: biologic activities that are independent of protease inhibition.Natural IgM-mediated innate autoimmunity: a new target for early intervention of ischemia-reperfusion injury.Common variation in the SERPING1 gene is not associated with age-related macular degeneration in two independent groups of subjects.Inhibition of complement improves graft outcome in a pig model of kidney autotransplantation.The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited.Role of complement and perspectives for intervention in ischemia-reperfusion damage.Two-dimensional difference gel electrophoresis (DIGE) analysis of sera from visceral leishmaniasis patients ON VASCULAR STENOSIS, RESTENOSIS AND MANNOSE BINDING LECTIN.Viral-derived complement inhibitors: current status and potential role in immunomodulation.Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases.New insight into the effects of heparinoids on complement inhibition by C1-inhibitor.Candida albicans Shaving to Profile Human Serum Proteins on Hyphal Surface.Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity.Complement inhibition attenuates acute kidney injury after ischemia-reperfusion and limits progression to renal fibrosis in mice.Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis.Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157:H7.Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway.StcE, a metalloprotease secreted by Escherichia coli O157:H7, specifically cleaves C1 esterase inhibitor.The effect of C1 inhibitor on intestinal ischemia and reperfusion injury.Refinement of tourniquet-induced peripheral ischemia/reperfusion injury in rats: comparison of 2 h vs 24 h reperfusion.Complement Dependence of Murine Costimulatory Blockade-Resistant Cellular Cardiac Allograft Rejection.Complement Activation During Ischemia/Reperfusion Injury Induces Pericyte-to-Myofibroblast Transdifferentiation Regulating Peritubular Capillary Lumen Reduction Through pERK Signaling.Meconium Is a Potent Activator of Complement in Human Serum and in Piglets

P2860

Q21090813-6B6D7FFB-211F-4FCD-B7C7-98B0E1023CA7 Q27027974-53EFD0E6-3233-41ED-A92A-558B3B2F57D6 Q27644724-A95B93D6-C3BE-446C-873D-549D00DB4EA2 Q28972362-F3A8303E-7AE1-434F-9B81-27A883DE3791 Q33655831-C643EA83-0ECA-4CC6-8AAF-77A05814033B Q33804415-692B4D00-3D04-474A-BE0D-0652C6A3EDC9 Q34450711-1E1EF498-58B6-428A-A045-DEB43F4D04AB Q34603645-7BEBE742-86AF-409E-96D3-4215A27E8D09 Q35053536-7FD86EF5-C25D-4CF5-86F7-3EEC18BE60C4 Q35098041-41DBD878-0BF0-4E62-8EB6-F69A28083842 Q35182755-8F6264CA-112D-40FC-84C0-95435715A0B6 Q35783719-BB545C46-533C-46B3-8A98-609DF2EFFAA4 Q36022738-F7046587-08E9-41FA-9B27-22A108DF6E95 Q36175011-A25C56B8-496C-456A-B3A0-BDF6CBF277B9 Q36253316-498FB933-C82F-49AC-8E1D-AE460C9666B0 Q36568742-9BB9E887-A98C-4ADD-AC00-7C93E8D6AC05 Q36572982-0853E7DF-EDC8-45A6-B360-D94ED07E7F57 Q36838407-FB0D5583-2136-4243-BE91-29F36A88166A Q36960513-60DE365D-2EA1-414B-8A80-084D49C42FC5 Q37069747-99E2522B-520A-4843-9030-D0D5E487992D Q37280720-9FB7FDEC-DDAA-4FF9-8F8A-5E8235FB3AE3 Q37644606-88E35907-1082-42D6-A5AF-5EBFC1A197D7 Q37831329-AA11A166-AF1B-41A3-BC96-0CCE89E400E4 Q38310999-2AEEEDC7-9AFD-4632-AA1D-361302E72916 Q38819108-3A4F4ACE-33B2-4896-8CD9-B4A4BAA7EB16 Q38995165-50ADA633-9871-4715-AC36-6D69CA9EFD62 Q39090725-24816C0D-47D5-47C6-88C7-EA77128BB75C Q39998832-F3686433-1CD0-49EB-9E27-F87B508F8FF7 Q40860112-FBFE0A2F-898C-4F4C-83DE-75903701EC14 Q41393053-3513459C-FBD4-4C92-A17F-CC77723B8BEA Q41497854-0775EF18-D665-48A0-967E-237D6874106F Q41665262-FCF8B46B-018D-41EA-B2CE-1ED9E1D82D08 Q42068191-E9EED6DD-39B8-4663-9F37-6B320B248936 Q43697611-323A23DF-FED4-4F41-8867-78B54FC18C24 Q44067982-BFCB3226-2092-42B8-BA44-8CAE2A685934 Q46372780-DF1C6678-FCC0-4F61-81D4-8C6D77DDC681 Q47904887-580820C6-BF9E-4D61-9736-AE2ED14A6C16 Q50699634-7389B097-28B2-4AD5-8172-EC5CFE23B489 Q55262251-F4514015-6995-4A40-BF15-CC72827E5B8A Q58143875-043A6F9A-6A4C-4380-9C14-CE5CFA6EDD57

P2860

Complement 1 inhibitor is a regulator of the alternative complement pathway

http://www.wikidata.org/entity/Q36369674

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh

2001年學術文章

@zh-hant

name

Complement 1 inhibitor is a regulator of the alternative complement pathway

@ast

Complement 1 inhibitor is a regulator of the alternative complement pathway

@en

type

label

Complement 1 inhibitor is a regulator of the alternative complement pathway

@ast

Complement 1 inhibitor is a regulator of the alternative complement pathway

@en

prefLabel

Complement 1 inhibitor is a regulator of the alternative complement pathway

@ast

Complement 1 inhibitor is a regulator of the alternative complement pathway

@en

P1433

Q36369674-912B8B62-1CAF-4F6D-8719-2E51D0E8B70B

P1476

Q36369674-E32794F5-0E0C-400D-9EC4-FC3E971A5D3B

P2093

Q36369674-53E490A0-E282-4613-BD02-33320DF0E9DC

Q36369674-940211CA-A6D1-46DD-A3B5-49A31351E7DE

Q36369674-E7722ECD-6374-4F09-B4FB-65FDBD00B2AC

Q36369674-EC9FA278-A720-4911-9A94-8E67B20EEBC6

P2860

Q36369674-596A2EA0-CCBE-4205-B160-E3F56A9ED43A

Q36369674-6E4383A5-B242-4533-AF7F-FA3A54BAE802

Q36369674-6E8951F1-302D-41BC-BB79-AFFCAC808960

Q36369674-90273579-51B1-4F9F-BFBA-2D071C43DCE1

Q36369674-A6C3B984-C04A-4F59-A281-9B70AF4CAD38

Q36369674-B65485EE-952E-4731-A786-2CFA84324704

Q36369674-E6DE4A38-6B30-46D4-BE15-6AB45C8DED20

Q36369674-F26AD1BB-602C-461E-A637-DFDC483A32ED

Q36369674-F55892BC-8749-4105-8B04-2CAEE8B23B1A

P304

Q36369674-33E5E3FA-19B3-4B7D-AED6-7ED356488E82

P31

Q36369674-DC8F1932-274A-4312-8348-9FDCF6045768

P356

Q36369674-A2885E3D-4849-436D-B200-1D9585B8CC75

P407

Q36369674-EF9BB968-FD4E-4714-9CD5-E8C957E044A8

P433

Q36369674-58630B4E-296B-4F8B-B40E-13A67AA33CF4

P478

Q36369674-BD2910BF-3432-4C43-B056-2D5B256AACEC

P577

Q36369674-B58A5093-89ED-454A-AA78-14E6E1A47F90

P5875

Q36369674-D74D85E8-3221-46B4-98FF-B1DD98658BA8

P698

Q36369674-1911A503-5D4C-40FC-823B-95C061FD0335

P932

Q36369674-09230F58-602B-4DBA-91B3-A9215546F5C4

P356

JEM.194.11.1609

P1433

Journal of Experimental Medicine

P1476

Complement 1 inhibitor is a regulator of the alternative complement pathway

@en

P2093

E Wagner

http://www.w3.org/2001/XMLSchema#string

H Jiang

http://www.w3.org/2001/XMLSchema#string

H Zhang

http://www.w3.org/2001/XMLSchema#string

M M Frank

http://www.w3.org/2001/XMLSchema#string

P2860

Proteolytic activities of two types of mannose-binding lectin-associated serine protease

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor

C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema.

Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria.

Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation.

Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.

Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema.

Interaction of plasma kallikrein with the C1 inhibitor.

P304

1609-1616

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.194.11.1609

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

194

http://www.w3.org/2001/XMLSchema#string

P577

2001-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11621915

http://www.w3.org/2001/XMLSchema#string

P698

11733575

http://www.w3.org/2001/XMLSchema#string

P932

2193533

http://www.w3.org/2001/XMLSchema#string